Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

January 19, 2017

NEW YORK, JANUARY 20, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) began a new clinical trial this week in Uzbekistan to develop a radically improved course of treatment for drug-resistant tuberculosis (DR-TB).

The trial aims to find a treatment regimen for DR-TB that is drastically shorter, more effective, and causes fewer side effects than the current treatment options.

February 24, 2015

Initial results of a clinical trial of the experimental drug favipiravir suggest that it can reduce mortality among patients with low levels of the Ebola virus in their blood, but is ineffective for patients with high viral loads who are very sick with the disease.

February 24, 2015

Initial results of a clinical trial of the experimental drug favipiravir suggest that it can reduce mortality among patients with low levels of the Ebola virus in their blood, but is ineffective for patients with high viral loads who are very sick with the disease.